Spots Global Cancer Trial Database for Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men

Official Title: Prostate Cancer Screening and Dietary HA Exposure in African-Americans: Phase II

Study ID: NCT00354497

Conditions

Prostate Cancer

Interventions

physiologic testing

study of socioeconomic and demographic variables

evaluation of cancer risk factors

mutation carrier screening

study of high risk factors

Study Description

Brief Summary: RATIONALE: Screening may help doctors find prostate cancer sooner, when it may be easier to treat. The amount of heterocyclic amines in the diet may affect prostate cancer screening results and the risk of prostate cancer. PURPOSE: This phase II trial is studying prostate cancer screening and dietary heterocyclic amines in African American men.

Detailed Description: OBJECTIVES: * Estimate dietary heterocyclic amine (HA) exposure in African American men who use HA-forming meats and cooking methods. * Correlate dietary HA exposure with prostate-specific antigen and digital rectal exam screening results (i.e., higher HA exposure with increased abnormality in prostate cancer screening results) in these participants. OUTLINE: This is a prospective study. Participants complete a routine medical questionnaire and undergo a detailed dietary interview that focuses on meat consumption, cooking preferences, and other factors that may be associated with prostate cancer risk. Participants then undergo a digital rectal exam (DRE) and blood collection for prostate-specific antigen (PSA) testing (total PSA and % free PSA). Results of PSA testing and DRE, including follow-up instructions (if needed), are sent to the participant 3-4 weeks later. Blood samples are also examined by phenotypic assays for UV-damage induced nucleotide excision-repair capacity. PROJECTED ACCRUAL: A total of 800 participants will be accrued for this study.